Double‐blind, Placebo‐controlled Antibiotic Treatment Study of Small Intestinal Bacterial Overgrowth in Children With Chronic Abdominal Pain

Abstract

Similar to adults with IBS, the prevalence of abnormal LBT suggesting SIBO in children with CAP is high; however, treatment with 10 days of rifaximin has low efficacy in normalizing LBT in this group. Additional studies are needed to determine whether a treatment approach with higher efficacy would lead to improvement in children with CAP.

Lactulose Hydrogen Breath Test and Functional Symptoms in Pediatric Patients

“…A recent study in children with chronic abdominal pain and abnormal LHBT, antibiotic treatment with rifaximin was not followed by improvement of symptoms compared to placebo and abnormal LBT persisted in 80% of them after 10 days of treatment [31].…”

Pharmacologic Treatment in Pediatric Functional Abdominal Pain Disorders: A Systematic Review

“…The RCT of Collins et al on rifaximin in children with chronic abdominal pain, for example, was, therefore, excluded. 57 Another limitation includes the possibility of bias in reporting outcomes because children aged 4-18 years are included and (part of) outcomes may be reported by parents. Sadeghian reported outcomes recorded by children and caregivers separately and both reported similar answers with respect to treatment response.…”

Current views on the etiopathogenesis, clinical manifestation, diagnostics, treatment and correlation with other nosological entities of SIBO

“…By way of comparison, in a group of healthy subjects, the result was 35% [45]. Pyleris et al proved that SIBO caused by aerobe bacteria is independently linked with IBS [46]. It is estimated that 25% of visits to a pediatric gastroenterologist's office concern problems related to CAP.…”